NextCure
NASDAQ: NXTCBeltsville, US · Founded 2015 · Delaware corporation · 9 known investors
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
Founders & leadership
NextCure was founded in 2015 by Michael Richman.
MR
Michael RichmanFounder
TM
Timothy MayerinExecutive
UG

Udayan GuhainExecutive
SP
Steven P. CobourninCFO
SK

Sourav KunduinExecutive
KS
Kevin ShawinExecutive
AR
ASHER RUBINExecutive
Board
EV
Elaine V. JonesBoard director
AB
Anne BorgmanBoard director
DK

TS

JL
Investors · 9
Bay City CapitalSan Rafael · $5M – $10M
Canaan PartnersStamford · $500K – $20Mvia Tim Shannon · board
LAVHong Kong · $5M – $15M
Lilly Asia VenturesHong Kongvia Hongbo Lu · inferred
Pfizer Venture Investments$5M – $20M
Quan CapitalShanghai
Sofinnova VenturesMenlo Park · $100K – $15M
Taiho Ventures, LLCMenlo Park
OrbiMedreportedNew York · $1M – $75Mvia Chau Khuong · board
Funding
SEC filings, press & company announcements$449.9M disclosed across 4 rounds · 2015–2026
- $320MraisedJul 2026Source ↗
▶$21.5MraisedDec 2025 · 12 investors · BiotechnologyRule 506(b)
▶$21.5MraisedDec 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy MayerExecutive Officer
- Michael RichmanExecutive Officer, Director
- Elaine V. JonesDirector
- Udayan GuhaExecutive Officer
- Anne BorgmanDirector
- Steven P. CobournExecutive Officer
- David KabakoffDirector
- Sourav KunduExecutive Officer
- Ellen FeigalDirector
- Stephen WebsterDirector
- John G. HoustonDirector
- Kevin ShawExecutive Officer
- Offering amount
- $21.5M
- Amount sold
- $21.5M
- Finders' fees
- $1.2M
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$93.4MraisedNov 2018 · 22 investors · BiotechnologyRule 506(b)
▶$93.4MraisedNov 2018 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stella XuDirector
- Michael RichmanExecutive Officer, Director
- Michael YiDirector
- Judith LiDirector
- Chau Q. KhuongDirector
- Kevin N. HellerExecutive Officer
- David KabakoffDirector
- Steven CobournExecutive Officer
- Tim ShannonDirector
- Elaine JonesDirector
- Offering amount
- $93.4M
- Amount sold
- $93.4M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$15MraisedJan 2016 · 7 investors · BiotechnologyRule 506(b)
▶$15MraisedJan 2016 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CAROLYN GREENDirector
- ASHER RUBINExecutive Officer
- DAVID KABAKOFFDirector
- TIM SHANNONDirector
- MICHAEL RICHMANExecutive Officer, Director
- JUDITH LIDirector
- CHAU Q. KHUONGDirector
- Offering amount
- $67M
- Amount sold
- $15M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does NextCure do?
- Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
- Who founded NextCure?
- NextCure was founded by Michael Richman in 2015.
- Who are NextCure's investors?
- NextCure's investors include Bay City Capital, Canaan Partners, LAV, Lilly Asia Ventures, Pfizer Venture Investments, Quan Capital, Sofinnova Ventures, Taiho Ventures, LLC and 1 more.
- How much funding has NextCure raised?
- NextCure has disclosed $449.9M raised across 4 rounds.
- Where is NextCure headquartered?
- NextCure is headquartered in Beltsville, US.


